Simple Summary Due to the lack of selectivity and the severe side-effects, cytostatics are the
drugs of the present but not of the future and consequently new anticancer strategies must …

Aprepitant is a selective high-affinity antagonist of human substance P (SP)/Neurokinin-1
(NK-1) receptors. Until now this drug has been used as anxiolytic, antidepressant and …

Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. To treat the
disease successfully, new therapeutic strategies are urgently needed. One of these …

The substance P (SP)/neurokinin (NK)-1 receptor system plays an important role in the
development of cancer. No in-depth studies of the involvement of this system in breast …

Introduction: The substance P (SP)/neurokinin (NK)-1 receptor system is involved in many
pathological processes. NK-1 receptor antagonists have many promising therapeutic …

Melanoma, the most deadly form of skin cancer, is aggressive and resistant to current
therapies. It has been previously reported that the substance P and neurokinin-1 (NK-1) …

The substance P (SP)/neurokinin (NK)-1 receptor system plays an important role in cancer.
SP promotes the proliferation of tumour cells, angiogenesis and the migration of tumour …

Simple Summary Improving the response, quality of life and survival of oncologic patients
through the design and application of the most appropriate treatment for each case is a great …

Aprepitant is a new neurokinin‐1 (NK1) receptor antagonist developed as a treatment for
chemotherapy‐induced nausea and vomiting (CINV). To evaluate the efficacy and safety of …

The implications of chemotherapeutic drug–drug interactions can be serious and thus need
to be addressed. This review concerns the potential interactions of the antiemetic aprepitant …